Beta-Thalassemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Beta-Thalassemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

Overview:

Beta-Thalassemia is an inherited blood disorder characterized by decreased levels of functional hemoglobin, which is the iron containing protein present in red blood cells that carries oxygen to the cells throughout the body. People with Beta-Thalassemia will be suffering from lack of oxygen supply in body and also shortage of red blood cells and will be at the increased risk of developing abnormal blood clots.

Symptoms of Beta-Thalassemia includes pale skin, jaundice, enlarged spleen, liver and heart, delayed puberty. Beta-Thalassemia can be diagnosed by molecular and genetic tests, blood tests etc. Treatment of Beta-Thalassemia includes frequent blood transfusions, bone marrow transplant, surgery to remove spleen or gallbladder and medications.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/beta-thalassemia-disease-pipeline-drugs-assessment/#ulp-4H8Z4LpNMLEuOnnx

Segmentation:

1. By Trial Phase, Beta-Thalassemiapipeline drugs are segmented as:
2. Preclinical Trials
3. Phase 1
4. Phase 2
5. Phase 3
6. Phase 4
7. By Company, Beta-Thalassemiapipeline drugs are segmented as:
8. Celgene Pharmaceuticals
9. bluebird bio.Inc
10. GlaxoSmithKline
11. Acceleron Pharma, Inc.
12. Sanofi
13. Novartis
14. HemaQuest Pharmaceuticals Inc.
15. Hoffmann-La Roche
16. FerroKinBioSciences, Inc.
17. Others
18. By Drugs, Beta-Thalassemia pipeline drugs are segmented as:
19. LentiGlobin
20. Deferitrin
21. Desferoxamine
22. Bitopertin
23. Deferasirox
24. Luspatercept
25. Zoledronic acid
26. Ambrisentan
27. Others
28. By Type of Condition, Beta-Thalassemia pipeline drugs are segmented as:
29. Thalassemia Major (Cooley’s anemia)
30. Thalassemia Intermedia
31. By Route of Administration, Beta-Thalassemiapipeline drugs are segmented as:
32. Oral
33. Parenteral

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/beta-thalassemia-disease-pipeline-drugs-assessment/#ulp-c654SbFYO64MsOhu

Space Analysis:

1. In October 2017, Sangamo Therapeutics and Bioverativreceived U.S.FDA IND acceptance to begin human clinical studies of ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia.
2. In September 2016, bluebird bio, Inc. commenced a phase III global multi center study of its HGB-207  in patients with transfusion-dependent beta-thalassemia with non-β⁰/β⁰genotypes
3. In May 2015, Luspatercept of Celgene Corporation and Acceleron Pharma Inc. was granted Fast track designations by U.S. FDA for two separate indications, for the treatment of patients with transfusion dependent beta-thalassemia and patients with non-transfusion dependent beta-thalassemia. Luspatercept is a modified activin receptor type IIB fusion protein that acts as a ligand trap for members of the Transforming Growth Factor-Beta (TGF-beta) superfamily involved in the late stages of erythropoiesis (red blood cell production). Luspatercept regulates late-stage erythrocyte (red blood cell) precursor cell differentiation and maturation

Report Description:

Beta-ThalassemiaDisease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Beta-Thalassemia treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Beta-Thalassemia disease pipeline drugs development. This report studies the dynamics of the Beta-Thalassemia Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Beta-Thalassemia disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/beta-thalassemia-disease-pipeline-drugs-assessment/#ulp-14mlyhjMGhVjZqa3

Key Features of the Report:

1. Provides the information related to universities and research institutes working in the therapeutics development
2. Report comprehensively covers the all active and discontinued studies
3. Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
4. Presents the prominent targets for drug development in each stage of clinical trial
5. Provides the in-depth analysis on the each drug candidates in the clinical trial phases

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/beta-thalassemia-disease-pipeline-drugs-assessment/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com